| C495626 | 14-deoxy-11,12-didehydroandrographolide | "14-deoxy-11,12-didehydroandrographolide results in increased expression of TFAP2A mRNA" | 22101062 |
| C046760 | 15-acetyldeoxynivalenol | 15-acetyldeoxynivalenol results in increased expression of TFAP2A mRNA | 23792671 |
| C019273 | 2,2-bis(4-glycidyloxyphenyl)propane | "2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Cytarabine results in increased expression of TFAP2A mRNA]" | 23264188 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| D000082 | Acetaminophen | Acetaminophen results in decreased expression of TFAP2A mRNA | 26690555 |
| D000082 | Acetaminophen | Acetaminophen results in increased expression of TFAP2A mRNA | 29067470 |
| C016601 | afimoxifene | afimoxifene results in decreased expression of TFAP2A mRNA | 19901195 |
| D016604 | Aflatoxin B1 | Aflatoxin B1 results in decreased methylation of TFAP2A gene | 27153756 |
| D018501 | Antirheumatic Agents | Antirheumatic Agents results in decreased expression of TFAP2A mRNA | 24449571 |
| C015001 | arsenite | arsenite results in decreased methylation of TFAP2A promoter | 23974009 |
| C487081 | belinostat | belinostat results in increased expression of TFAP2A mRNA | 26272509 |
| C487081 | belinostat | "[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in decreased expression of TFAP2A mRNA | 22228805 |
| D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | "7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of TFAP2A mRNA" | 19150397|2001819 |
| D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | "7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of TFAP2A mRNA" | 17944540 |
| D004958 | Estradiol | Estradiol affects the expression of TFAP2A mRNA | 23557687 |
| D004958 | Estradiol | Estradiol results in decreased expression of TFAP2A mRNA | 26865669|2871154 |
| C006780 | bisphenol A | bisphenol A affects the expression of TFAP2A mRNA | 23557687 |
| C006780 | bisphenol A | bisphenol A affects the methylation of TFAP2A promoter | 27334623 |
| C006780 | bisphenol A | bisphenol A results in decreased expression of TFAP2A mRNA | 25181051 |
| C027561 | butylbenzyl phthalate | butylbenzyl phthalate affects the localization of TFAP2A protein | 22552774 |
| C027561 | butylbenzyl phthalate | butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter] | 22552774 |
| C027561 | butylbenzyl phthalate | [butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]] which results in increased expression of HDAC6 mRNA | 22552774 |
| C027561 | butylbenzyl phthalate | N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein] | 22552774 |
| C027561 | butylbenzyl phthalate | TFAP2A mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of HDAC6 protein] | 22552774 |
| C027561 | butylbenzyl phthalate | tyrphostin AG 1478 inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein] | 22552774 |
| C018475 | butyraldehyde | butyraldehyde results in decreased expression of TFAP2A mRNA | 26079696 |
| D000068579 | Celecoxib | Celecoxib results in decreased expression of TFAP2A mRNA | 28201806 |
| D020245 | p-Chloromercuribenzoic Acid | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| D020245 | p-Chloromercuribenzoic Acid | p-Chloromercuribenzoic Acid results in increased expression of TFAP2A mRNA | 26272509 |
| D002794 | Choline | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of TFAP2A gene | 20938992 |
| C059262 | cidofovir | cidofovir results in decreased expression of TFAP2A mRNA | 25596134 |
| D004002 | Clodronic Acid | Clodronic Acid results in decreased expression of TFAP2A mRNA | 25596134 |
| D002996 | Clomiphene | Clomiphene results in increased expression of TFAP2A mRNA | 26865669 |
| D003300 | Copper | Copper results in decreased expression of TFAP2A mRNA | 26293553 |
| D003471 | Cuprizone | Cuprizone results in increased expression of TFAP2A mRNA | 27523638 |
| D016572 | Cyclosporine | Cyclosporine results in decreased expression of TFAP2A mRNA | 25596134 |
| D003561 | Cytarabine | "2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Cytarabine results in increased expression of TFAP2A mRNA]" | 23264188 |
| D003561 | Cytarabine | Cytarabine results in increased expression of TFAP2A mRNA | 23264188 |
| C014347 | decitabine | decitabine results in increased expression of TFAP2A mRNA | 16204029 |
| C014347 | decitabine | decitabine results in increased expression of TFAP2A protein | 16204029 |
| C014347 | decitabine | [decitabine results in increased expression of TFAP2A protein] which results in increased susceptibility to Cisplatin | 16204029 |
| C014347 | decitabine | [decitabine results in increased expression of TFAP2A protein] which results in increased susceptibility to Doxorubicin | 16204029 |
| D003703 | Demecolcine | Demecolcine results in decreased expression of TFAP2A mRNA | 23649840 |
| D003907 | Dexamethasone | Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of TFAP2A mRNA] | 27941970 |
| D003907 | Dexamethasone | Dexamethasone results in increased expression of TFAP2A protein | 28453788 |
| D016190 | Carboplatin | TFAP2A protein results in increased susceptibility to Carboplatin | 16204029 |
| D003993 | Dibutyl Phthalate | Dibutyl Phthalate affects the localization of TFAP2A protein | 22552774 |
| D003993 | Dibutyl Phthalate | Dibutyl Phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter] | 22552774 |
| D003993 | Dibutyl Phthalate | [Dibutyl Phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]] which results in increased expression of HDAC6 mRNA | 22552774 |
| D003993 | Dibutyl Phthalate | N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein] | 22552774 |
| D003993 | Dibutyl Phthalate | TFAP2A mutant form inhibits the reaction [Dibutyl Phthalate results in increased expression of HDAC6 protein] | 22552774 |
| D003993 | Dibutyl Phthalate | tyrphostin AG 1478 inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein] | 22552774 |
| D002945 | Cisplatin | Cisplatin results in decreased expression of TFAP2A mRNA | 25596134 |
| D002945 | Cisplatin | Cisplatin results in increased expression of TFAP2A protein | 16204029 |
| D002945 | Cisplatin | [decitabine results in increased expression of TFAP2A protein] which results in increased susceptibility to Cisplatin | 16204029 |
| D002945 | Cisplatin | TFAP2A protein affects the susceptibility to Cisplatin | 16217747 |
| D002945 | Cisplatin | [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to Cisplatin | 21489314 |
| D002945 | Cisplatin | TFAP2A protein results in increased susceptibility to Cisplatin | 16204029|2148931 |
| C036042 | dicyclohexyl phthalate | dicyclohexyl phthalate results in increased expression of TFAP2A mRNA | 26924002 |
| D018119 | Stavudine | Stavudine results in decreased expression of TFAP2A mRNA | 17926646 |
| D004041 | Dietary Fats | Dietary Fats results in increased expression of TFAP2A mRNA | 25016146 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol results in decreased expression of TFAP2A mRNA | 26865669 |
| D002117 | Calcitriol | Calcitriol results in increased expression of TFAP2A mRNA | 26485663 |
| C024629 | dimethyl phthalate | dimethyl phthalate affects the expression of TFAP2A mRNA | 26924002 |
| D004317 | Doxorubicin | [decitabine results in increased expression of TFAP2A protein] which results in increased susceptibility to Doxorubicin | 16204029 |
| D004317 | Doxorubicin | Doxorubicin results in increased expression of TFAP2A protein | 16204029 |
| D004317 | Doxorubicin | TFAP2A protein results in increased susceptibility to Doxorubicin | 16204029 |
| C118739 | entinostat | entinostat results in increased expression of TFAP2A mRNA | 26272509 |
| C118739 | entinostat | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter] | 21499124|2195155 |
| D000069347 | Erlotinib Hydrochloride | Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] | 21499124|2195155 |
| D000431 | Ethanol | Ethanol results in decreased expression of TFAP2A protein | 28919490 |
| D000431 | Ethanol | Ethanol results in increased expression of TFAP2A mRNA | 28986285 |
| D008656 | Mestranol | Mestranol results in decreased expression of TFAP2A mRNA | 26865669 |
| D005047 | Etoposide | TFAP2A protein affects the susceptibility to Etoposide | 16217747 |
| D005047 | Etoposide | TFAP2A protein results in increased susceptibility to Etoposide | 16204029 |
| D018690 | Excitatory Amino Acid Agonists | Excitatory Amino Acid Agonists results in increased expression of and results in increased activity of TFAP2A protein | 17550430 |
| D005492 | Folic Acid | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of TFAP2A gene | 20938992 |
| C070081 | fulvestrant | fulvestrant results in increased expression of TFAP2A mRNA | 26865669 |
| C039281 | furan | furan results in increased expression of TFAP2A mRNA | 25539665 |
| C419708 | gefitinib | gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter] | 21499124|2195155 |
| C419708 | gefitinib | Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] | 21499124|2195155 |
| C056507 | gemcitabine | [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to gemcitabine | 21489314 |
| C056507 | gemcitabine | TFAP2A protein results in increased susceptibility to gemcitabine | 21489314 |
| D019833 | Genistein | Genistein results in decreased expression of TFAP2A mRNA | 26865669 |
| D006589 | Hexestrol | Hexestrol results in decreased expression of TFAP2A mRNA | 26865669 |
| D017313 | Fenretinide | Fenretinide results in increased expression of TFAP2A mRNA | 28973697 |
| D007069 | Ifosfamide | Ifosfamide results in decreased expression of TFAP2A mRNA | 25596134 |
| D019469 | Indinavir | Indinavir results in decreased expression of TFAP2A mRNA | 17926646 |
| C544151 | jinfukang | jinfukang results in increased expression of TFAP2A mRNA | 27392435 |
| D008345 | Manganese | Manganese results in increased expression of TFAP2A protein | 24845367 |
| C042720 | mercuric bromide | mercuric bromide results in increased expression of TFAP2A mRNA | 26272509 |
| C042720 | mercuric bromide | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| D008694 | Methamphetamine | Methamphetamine results in increased expression of TFAP2A mRNA | 28341135 |
| D008715 | Methionine | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of TFAP2A gene | 20938992 |
| D008727 | Methotrexate | Methotrexate affects the expression of TFAP2A mRNA | 18502557 |
| C004925 | methylmercuric chloride | methylmercuric chloride results in decreased expression of TFAP2A mRNA | 28001369 |
| C004925 | methylmercuric chloride | methylmercuric chloride results in increased expression of TFAP2A mRNA | 23179753|2627250 |
| D016685 | Mitomycin | TFAP2A protein affects the susceptibility to Mitomycin | 16217747 |
| C517284 | monomethyl phthalate | monomethyl phthalate affects the expression of TFAP2A mRNA | 26924002 |
| C063509 | N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide | N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein] | 22552774 |
| C063509 | N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide | N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein] | 22552774 |
| C017557 | nickel subsulfide | nickel subsulfide results in decreased expression of TFAP2A mRNA | 12760830 |
| D010126 | Ozone | Ozone promotes the reaction [TFAP2A protein binds to BRS3 promoter] | 17355223 |
| D010126 | Ozone | Ozone results in increased activity of TFAP2A protein | 17355223 |
| D010126 | Ozone | TFAP2A protein affects the reaction [Ozone results in increased expression of BRS3 mRNA] | 17355223 |
| D017239 | Paclitaxel | Paclitaxel results in increased expression of TFAP2A protein | 16204029 |
| D017239 | Paclitaxel | TFAP2A protein results in increased susceptibility to Paclitaxel | 16204029 |
| C496932 | panobinostat | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C496932 | panobinostat | panobinostat results in increased expression of TFAP2A mRNA | 26272509 |
| D017374 | Paroxetine | Paroxetine results in increased expression of TFAP2A protein | 28844482 |
| D052638 | Particulate Matter | Particulate Matter results in increased expression of TFAP2A mRNA | 21703343 |
| D010662 | Phenylmercuric Acetate | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| D010662 | Phenylmercuric Acetate | Phenylmercuric Acetate results in increased expression of TFAP2A mRNA | 26272509 |
| D010795 | Phthalic Acids | Phthalic Acids results in decreased expression of TFAP2A mRNA | 21061450 |
| C006253 | pirinixic acid | pirinixic acid results in increased expression of TFAP2A mRNA | 18445702 |
| D010936 | Plant Extracts | Plant Extracts results in decreased expression of TFAP2A mRNA | 23684756 |
| D011441 | Propylthiouracil | Propylthiouracil results in increased expression of TFAP2A mRNA | 24780913 |
| D020849 | Raloxifene Hydrochloride | Raloxifene Hydrochloride results in increased expression of TFAP2A mRNA | 26865669 |
| C059514 | resveratrol | resveratrol results in increased localization of and results in increased activity of TFAP2A protein | 16488535 |
| C085746 | rottlerin | rottlerin inhibits the reaction [TFAP2A protein binds to ULBP1 promoter] | 21499124 |
| C078903 | seocalcitol | seocalcitol results in increased expression of TFAP2A mRNA | 12040012 |
| D020280 | Sertraline | Sertraline results in increased expression of TFAP2A protein | 28844482 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of TFAP2A mRNA | 19901195|2290382 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of TFAP2A mRNA | 21570461|2405805 |
| D013749 | Tetrachlorodibenzodioxin | TFAP2A mRNA affects the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein] | 16085934 |
| D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] | 21499124|2195155 |
| D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] | 21499124|2195155 |
| D014212 | Tretinoin | Tretinoin results in increased expression of TFAP2A mRNA | 14534139 |
| D014212 | Tretinoin | Tretinoin affects the localization of TFAP2A protein | 17229153 |
| D014212 | Tretinoin | Tretinoin inhibits the reaction [TFAP2A protein binds to DPYSL2 promoter] | 17229153 |
| D014212 | Tretinoin | Tretinoin promotes the reaction [NPM1 protein binds to TFAP2A protein] | 17318229 |
| D014212 | Tretinoin | Tretinoin promotes the reaction [[NPM1 protein binds to TFAP2A protein] which binds to NPM1 promoter] | 17318229 |
| D014212 | Tretinoin | Tretinoin results in increased expression of TFAP2A mRNA | 17138961|1731822 |
| D014241 | Trichloroethylene | Trichloroethylene results in increased expression of TFAP2A mRNA | 21135412 |
| C012589 | trichostatin A | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C012589 | trichostatin A | trichostatin A results in increased expression of TFAP2A mRNA | 24935251|2627250 |
| C101044 | tyrphostin AG 1478 | tyrphostin AG 1478 inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein] | 22552774 |
| C101044 | tyrphostin AG 1478 | tyrphostin AG 1478 inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein] | 22552774 |
| D014635 | Valproic Acid | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| D014635 | Valproic Acid | Valproic Acid affects the expression of TFAP2A mRNA | 25979313 |
| D014635 | Valproic Acid | Valproic Acid results in decreased expression of TFAP2A mRNA | 28001369 |
| D014635 | Valproic Acid | Valproic Acid results in decreased methylation of TFAP2A gene | 29154799 |
| D014635 | Valproic Acid | Valproic Acid results in increased expression of TFAP2A mRNA | 23179753|2438349 |
| D014635 | Valproic Acid | Valproic Acid affects the expression of TFAP2A mRNA | 17292431 |
| D001335 | Vehicle Emissions | Vehicle Emissions results in decreased methylation of TFAP2A gene | 25560391 |
| D014750 | Vincristine | Vincristine results in decreased expression of TFAP2A mRNA | 23649840 |
| C111237 | vorinostat | "[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA" | 27188386 |
| C111237 | vorinostat | vorinostat results in increased expression of TFAP2A mRNA | 26272509 |
| D015215 | Zidovudine | Zidovudine results in decreased expression of TFAP2A mRNA | 17926646 |